Robert P Frantz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9157924/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	2.8	1,467
2	Predicting Survival in Pulmonary Arterial Hypertension. Circulation, 2010, 122, 164-172.	1.6	1,353
3	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	6.7	614
4	The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Chest, 2012, 141, 354-362.	0.8	448
5	Predicting Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2019, 156, 323-337.	0.8	408
6	Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2013, 6, 711-721.	2.6	349
7	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 41, 1380-1386.	2.8	334
8	Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology, 2006, 44, 1502-1510.	7.3	322
9	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq1	1 00788431	l4 ng⊠T /Over
10	Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2011, 139, 1299-1309.	0.8	298
11	Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology, 1999, 30, 641-648.	7.3	271
12	Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ, The, 2016, 353, i1246.	6.0	266
13	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation, 2018, 137, 1796-1810.	1.6	223
14	Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Circulation, 2009, 120, 2170-2176.	1.6	213
15	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2012. 31. 913-933.	0.6	210
16	Readmissions After Implantation of Axial Flow Left Ventricular Assist Device. Journal of the American College of Cardiology, 2013, 61, 153-163.	2.8	209
17	Accuracy of Doppler Echocardiography in the Assessment of Pulmonary Hypertension in Liver Transplant Candidates. Liver Transplantation, 2000, 6, 453-458.	2.4	176
18	Changes in Renal Function After Implantation of Continuous-Flow Left Ventricular Assist Devices. Journal of the American College of Cardiology, 2012, 59, 26-36.	2.8	167

#	Article	IF	CITATIONS
19	Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. Circulation, 2007, 116, 2726-2733.	1.6	162
20	Endothelial Progenitor Cells Are Decreased in Blood of Cardiac Allograft Patients With Vasculopathy and Endothelial Cells of Noncardiac Origin Are Enriched in Transplant Atherosclerosis. Circulation, 2003, 108, 143-149.	1.6	142
21	Acute Cellular Rejection and the Subsequent Development of Allograft Vasculopathy After Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 320-327.	0.6	141
22	Role of Serial Quantitative Assessment of Right Ventricular Function by Strain in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2013, 111, 143-148.	1.6	137
23	Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2011, 139, 1285-1293.	0.8	124
24	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
25	Combined Heart and Liver Transplantation: A Single-Center Experience. Transplantation, 2009, 88, 219-225.	1.0	118
26	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. Journal of Heart and Lung Transplantation, 2008, 27, 823-829.	0.6	117
27	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	4.5	113
28	Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. Mayo Clinic Proceedings, 2003, 78, 1207-1213.	3.0	109
29	Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome. Circulation: Cardiovascular Imaging, 2011, 4, 648-661.	2.6	106
30	Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension. Circulation: Heart Failure, 2013, 6, 748-755.	3.9	106
31	Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation. Circulation, 2012, 125, 708-720.	1.6	105
32	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.6	103
33	Sirolimus in Cardiac Transplantation: Use as a Primary Immunosuppressant in Calcineurin Inhibitor–induced Nephrotoxicity. Journal of Heart and Lung Transplantation, 2005, 24, 2129-2136.	0.6	90
34	Pericardial Effusions in Pulmonary Arterial Hypertension. Chest, 2013, 144, 1530-1538.	0.8	81
35	Long-Term Sirolimus for PrimaryÂlmmunosuppression in HeartÂTransplantÂRecipients. Journal of the American College of Cardiology, 2018, 71, 636-650.	2.8	81
36	Relation of Tissue Displacement and Strain to Invasively Determined Right Ventricular Stroke Volume. American Journal of Cardiology, 2005, 96, 1173-1178.	1.6	79

#	Article	IF	CITATIONS
37	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Metaâ€Analysis. Echocardiography, 2015, 32, 787-796.	0.9	79
38	Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients. Transplantation, 2007, 84, 467-474.	1.0	73
39	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	5.6	68
40	Causes of Breathing Inefficiency During Exercise in Heart Failure. Journal of Cardiac Failure, 2010, 16, 835-842.	1.7	65
41	Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy. Transplantation, 2013, 95, 389-396.	1.0	65
42	Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. Journal of Heart and Lung Transplantation, 2012, 31, 1102-1108.	0.6	64
43	Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With β-Blockade in Patients With Heart Failure. Circulation, 2003, 108, 2336-2341.	1.6	63
44	Clinical predictors of exercise capacity 1 year after cardiac transplantation. Journal of Heart and Lung Transplantation, 2003, 22, 16-27.	0.6	62
45	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBl–Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	5.6	59
46	Increase in Total Plasma Homocysteine Concentration After Cardiac Transplantation. Mayo Clinic Proceedings, 1995, 70, 125-131.	3.0	58
47	Usefulness of the Six-Minute Walk Test After Continuous Axial Flow Left Ventricular Device Implantation to Predict Survival. American Journal of Cardiology, 2012, 110, 1322-1328.	1.6	56
48	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation, 2016, 6, 380.	1.6	56
49	Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2007, 26, 826-833.	0.6	55
50	Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. American Heart Journal, 2005, 149, 541-547.	2.7	54
51	Combined Heart and Kidney Transplantation Provides an Excellent Survival and Decreases Risk of Cardiac Cellular Rejection and Coronary Allograft Vasculopathy. Transplantation Proceedings, 2011, 43, 1871-1876.	0.6	52
52	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. Journal of the American Heart Association, 2022, 11, e024969.	3.7	50
53	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. Chest, 2016, 150, 27-34.	0.8	48
54	Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. American Heart Journal, 2007, 153, 104.e1-104.e7.	2.7	47

#	Article	IF	CITATIONS
55	Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. Transplantation, 2008, 86, 1395-1400.	1.0	45
56	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 1179-1186.	0.6	42
57	Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Crossâ€Sectional Survey. Pulmonary Circulation, 2014, 4, 504-510.	1.7	42
58	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire. Chest, 2018, 154, 848-861.	0.8	41
59	Right Ventricular Pressure Waveform and Wave Reflection Analysis in Patients With Pulmonary Arterial Hypertension. Chest, 2007, 132, 37-43.	0.8	40
60	Unraveling the RV Ejection DopplerÂEnvelope. JACC: Cardiovascular Imaging, 2017, 10, 1268-1277.	5.3	40
61	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2018, 154, 126-135.	0.8	40
62	Partial Normalization of the Heart Rate Response to Exercise After Cardiac Transplantation: Frequency and Relationship to Exercise Capacity. Mayo Clinic Proceedings, 2002, 77, 1295-1300.	3.0	38
63	The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 1133-1142.	0.6	38
64	The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction. Journal of Cardiac Failure, 2008, 14, 267-275.	1.7	37
65	Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 780-788.	0.6	36
66	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. Journal of Heart and Lung Transplantation, 2021, 40, 1301-1326.	0.6	36
67	Combined Heart and Liver Transplant Attenuates Cardiac Allograft Vasculopathy Compared with Isolated Heart Transplantation. Transplantation, 2013, 95, 859-865.	1.0	35
68	Imatinib in Pulmonary Arterial Hypertension: Câ€Kit Inhibition. Pulmonary Circulation, 2014, 4, 452-455.	1.7	35
69	Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study. Chest, 2015, 147, 484-494.	0.8	35
70	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. European Journal of Applied Physiology, 2008, 103, 421-430.	2.5	34
71	Cardiac Allograft Remodeling After Heart Transplantation Is Associated with Increased Graft Vasculopathy and Mortality. American Journal of Transplantation, 2009, 9, 132-139.	4.7	34
72	The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension. Clinical Respiratory Journal, 2018, 12, 1572-1580.	1.6	34

#	Article	IF	CITATIONS
73	Impact of Right Ventricular Dysfunction on Short-term and Long-term Mortality in Sepsis. Chest, 2021, 159, 2254-2263.	0.8	33
74	Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. Chest, 2016, 149, 362-371.	0.8	31
75	Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. American Heart Journal, 2007, 153, 426-432.	2.7	30
76	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 311-318.	2.4	29
77	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 696-705.	0.6	28
78	Right ventricular function with hypoxic exercise: effects of sildenafil. European Journal of Applied Physiology, 2007, 102, 87-95.	2.5	27
79	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. Circulation: Heart Failure, 2020, 13, e006363.	3.9	27
80	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	5.6	27
81	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.8	26
82	United States Pulmonary Hypertension Scientific Registry. Chest, 2021, 159, 311-327.	0.8	25
83	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. European Respiratory Journal, 2021, 57, 2000414.	6.7	24
84	Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2016, 118, 292-297.	1.6	22
85	Heart transplantation for radiation-associated end-stage heart failure. Transplant International, 2000, 13, 162-165.	1.6	21
86	B-Type Natriuretic Peptide Levels and Continuous-Flow Left Ventricular Assist Devices. ASAIO Journal, 2010, 56, 527-531.	1.6	21
87	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. Journal of the American Heart Association, 2019, 8, e012073.	3.7	21
88	Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension. Journal of Cardiac Failure, 2015, 21, 647-655.	1.7	20
89	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1506-1513.	1.3	20
90	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension. Chest, 2020, 158, 2568-2578.	0.8	20

#	Article	IF	CITATIONS
91	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. European Journal of Applied Physiology, 2009, 106, 509-515.	2.5	19
92	Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuousâ€Flow Left Ventricular Assist Devices. Journal of the American Heart Association, 2019, 8, e013108.	3.7	19
93	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. Journal of Heart and Lung Transplantation, 2018, 37, 948-955.	0.6	18
94	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 229-237.	3.2	18
95	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. Journal of the American College of Cardiology, 2021, 77, 1331-1340.	2.8	18
96	Recipient Selection and Management Before Cardiac Transplantation. American Journal of the Medical Sciences, 1997, 314, 139-152.	1.1	18
97	Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST). Journal of Cardiac Failure, 2007, 13, 437-444.	1.7	17
98	Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. Journal of Heart and Lung Transplantation, 2012, 31, 811-816.	0.6	17
99	A Pulmonary Hypertension Gas Exchange Severity (PH-GXS) Score to Assist With the Assessment and Monitoring of Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 109, 1066-1072.	1.6	17
100	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenetics and Genomics, 2013, 23, 658-665.	1.5	17
101	Novel Left Heart Catheterization Ramp Protocol to Guide Hemodynamic Optimization in Patients Supported With Left Ventricular Assist Device Therapy. Journal of the American Heart Association, 2019, 8, e010232.	3.7	17
102	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2021, 11, 1-10.	1.7	17
103	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2022, 10, 35-46.	10.7	17
104	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.6	17
105	Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and Increased Risk of Cardiovascular Events in Heart Transplant Patients. Transplantation, 2008, 85, 963-968.	1.0	16
106	Totally Implantable IV Treprostinil TherapyÂin Pulmonary Hypertension Assessment of the Implantation Procedure. Chest, 2017, 152, 1128-1134.	0.8	16
107	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase typeâ€5Âinhibitors. Pulmonary Circulation, 2020, 10, 1-11.	1.7	15
108	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thrombosis and Haemostasis, 2012, 108, 1049-1060.	3.4	14

#	Article	IF	CITATIONS
109	A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost. Pulmonary Circulation, 2013, 3, 381-388.	1.7	14
110	Conversion From Sildenafil to Tadalafil. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 550-557.	2.0	14
111	Treadmill testing improves survival prediction models in pulmonary arterial hypertension. American Heart Journal, 2011, 162, 1011-1017.	2.7	13
112	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1153-1160.	0.6	12
113	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class <scp>IV</scp> Chronic Thromboembolic Pulmonary Hypertension. Pharmacotherapy, 2017, 37, e76-e81.	2.6	12
114	Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. Pulmonary Circulation, 2019, 9, 204589401987861.	1.7	12
115	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 761-764.	5.6	12
116	The Pharmacokinetics of Racemic Verapamil in Patients with Impaired Renal Function. Journal of Clinical Pharmacology, 1991, 31, 45-53.	2.0	11
117	Techniques of Immunosuppression After Cardiac Transplantation. Mayo Clinic Proceedings, 1992, 67, 586-595.	3.0	11
118	A Possible Role for Systemic Hypoxia in the Reactive Component of Pulmonary Hypertension in Heart Failure. Journal of Cardiac Failure, 2013, 19, 50-59.	1.7	11
119	Hemodynamic Ranges During Daily Activities and Exercise Testing in Patients With Pulmonary Arterial Hypertension. Journal of Cardiac Failure, 2014, 20, 485-491.	1.7	11
120	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. Journal of Heart and Lung Transplantation, 2018, 37, 1372-1380.	0.6	11
121	Thrombocytopenia independently predicts death in idiopathic PAH. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 34-38.	1.6	11
122	EFFECTS OF PENTOXIFYLLINE ON RENAL FUNCTION AND BLOOD PRESSURE IN CARDIAC TRANSPLANT RECIPIENTS. Transplantation, 1997, 63, 1607-1610.	1.0	11
123	Early Trends in N-Terminal Pro–Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure. American Journal of Cardiology, 2014, 114, 1257-1263.	1.6	10
124	Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. Respiratory Medicine Case Reports, 2015, 14, 13-15.	0.4	10
125	Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year. ASAIO Journal, 2017, 63, 401-407.	1.6	10
126	Whither Anticoagulation in Pulmonary Arterial Hypertension?. Circulation, 2015, 132, 2360-2362.	1.6	8

#	Article	IF	CITATIONS
127	Hemodynamic monitoring in pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2011, 5, 173-178.	2.5	7
128	Features of Cardiac Allograft Coronary Endothelial Dysfunction. American Journal of Cardiology, 2009, 103, 1154-1158.	1.6	6
129	Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm. European Respiratory Journal, 2015, 46, 299-302.	6.7	6
130	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary BalloonÂAngioplasty for Chronic Pulmonary Thromboembolism. JACC: Cardiovascular Interventions, 2017, 10, 532-534.	2.9	6
131	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. Pulmonary Circulation, 2019, 9, 204589401984561.	1.7	6
132	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. European Heart Journal Cardiovascular Imaging, 2022, 23, 958-969.	1.2	6
133	REPLACE and the role of riociguat in pulmonary arterial hypertension therapy. Lancet Respiratory Medicine,the, 2021, 9, 546-547.	10.7	6
134	Topic-Based, Recent Literature Review on Pulmonary Hypertension. Mayo Clinic Proceedings, 2021, 96, 3109-3121.	3.0	6
135	Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011315.	3.9	6
136	Characterization of Prostacyclin-associated Leg Pain in Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 206-212.	3.2	6
137	Beta blockade in patients with congestive heart failure. Postgraduate Medicine, 2000, 108, 103-118.	2.0	5
138	Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing oneâ€day versus sevenâ€day symptom reporting. Pulmonary Circulation, 2020, 10, 1-9.	1.7	5
139	Resolution of severe pulmonary arterial hypertension complicating adult-onset Still's disease. Journal of Heart and Lung Transplantation, 2016, 35, 1140-1144.	0.6	4
140	The Usefulness of Submaximal Exercise Gas Exchange in Pulmonary Arterial Hypertension: A Case Series. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2010, 4, 117954842020100.	0.9	3
141	COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No. Chest, 2020, 157, 766-768.	0.8	3
142	The usefulness of submaximal exercise gas exchange in pulmonary arterial hypertension: a case series. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2010, 4, 35-40.	0.9	3
143	Response to Letter Regarding Article, "Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial― Circulation, 2010, 122, .	1.6	1
144	Donor Pre-Treatment With Dopamine. Journal of the American College of Cardiology, 2011, 58, 1778-1779.	2.8	1

#	Article	IF	CITATIONS
145	Diagnostic Dilemmas in Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 331-352.	2.1	1
146	Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2008, 7, 405-410.	0.1	1
147	Pulmonary Hypertension in Chronic Heart and Lung Disease. Respiratory Medicine, 2015, , 93-113.	0.1	1
148	Mateâ€pair sequencing identifies a cryptic <i>BMPR2</i> mutation in hereditary pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	1.7	1
149	Recipient Selection and Management Before Cardiac Transplantation. American Journal of the Medical Sciences, 1997, 314, 139-152.	1.1	0
150	Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence. Future Cardiology, 2008, 4, 459-468.	1.2	0
151	Response. Chest, 2018, 154, 1262-1264.	0.8	0
152	Rebuttal From Dr Frantz. Chest, 2020, 157, 768-769.	0.8	0
153	Cardiac and Lung Transplantation and the Right Heart. , 2021, , 317-329.		0
154	The effects of sildenafil and acetazolamide on breathing efficiency during hypoxic exercise. FASEB Journal, 2008, 22, 1173.13.	0.5	0
155	Cardiac and Lung Transplantation. , 2014, , 291-303.		0
156	PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved. Advances in Pulmonary Hypertension, 2014, 13, 65-67.	0.1	0
157	The Future of Pulmonary Hypertension. , 2016, , 359-367.		0
158	Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape. Advances in Pulmonary Hypertension, 2017, 15, 193-197.	0.1	0